Sinovac Biotech Ltd SVA
News
-
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
-
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
-
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
-
SINOVAC Reports Unaudited First Half of 2025 Financial Results
-
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Trading Information
- Previous Close Price
- —
- Day Range
- $0.00–0.00
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 60.06M
- Market Cap
- $0.00
- Volume/Avg
- 2,455 / 0
Key Statistics
- Price/Earnings (Normalized)
- 23.52
- Price/Sales
- 1.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its products include vaccines for hepatitis A, hepatitis B, EV-A71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella, mumps, and tetanus. The Company generates maximum revenue from Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,643
- Website
- http://www.sinovac.com
Valuation
|
Metric
|
SVA
|
|---|---|
Price/Earnings (Normalized) | 23.52 |
Price/Book Value | 1.82 |
Price/Sales | 1.83 |
Price/Cash Flow | 8.10 |
Price/Earnings
SVA
Financial Strength
|
Metric
|
SVA
|
|---|---|
Quick Ratio | 4.08 |
Current Ratio | 4.59 |
Interest Coverage | −29.08 |
Quick Ratio
SVA
Profitability
|
Metric
|
SVA
|
|---|---|
Return on Assets (Normalized) | −0.38% |
Return on Equity (Normalized) | −0.72% |
Return on Invested Capital (Normalized) | −0.73% |
Return on Assets
SVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Hdvwcflr | Rdfwv | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hkjtcjqpl | Rnwcthv | $67B | |||
| argenx SE ADR
ARGX
| Wzyldhkg | Bpzs | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wvymwgd | Dmkgl | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Lbdvwtpys | Hdfmp | $25B | |||
| BioNTech SE ADR
BNTX
| Ddmhvljh | Wkczx | $22B | |||
| Incyte Corp
INCY
| Nsrnrhsqt | Wwyj | $20B | |||
| Moderna Inc
MRNA
| Tfhblnfj | Pqt | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Bcphbpwp | Lnvz | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Ztdjdddq | Rbk | $13B |
United States